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Abstract
Objective The objective of this study was to estimate the relative cost effectiveness for the full range of uterotonic drugs 
available for preventing postpartum haemorrhage (PPH).
Methods A model-based economic evaluation was constructed using effectiveness data from a network meta-analysis, and 
supplemented by the literature. A UK National Health Service (NHS) perspective was adopted for the analysis, which is 
based on UK costs from published sources. The primary outcome measure is cost per case of PPH avoided (≥ 500 mL blood 
loss), with secondary outcome measures of cost per case of severe PPH avoided (≥ 1000 mL) and cost per major outcome 
(surgery) averted also being analysed.
Results Carbetocin is shown to be the most effective strategy. Excluding adverse events, ‘ergometrine plus oxytocin’ was 
shown to be the least costly strategy. The incremental cost-effectiveness ratio for prevention of PPH with carbetocin com-
pared with prevention with ‘ergometrine plus oxytocin’ was £1889 per case of PPH ≥ 500 mL avoided; £30,013 per case of 
PPH ≥ 1000 mL avoided; and £1,172,378 per major outcome averted. Including adverse events in the analysis showed oxy-
tocin to be the least costly strategy. The incremental cost-effectiveness ratio for prevention of PPH with carbetocin compared 
with prevention with oxytocin was £928 per case of PPH ≥ 500 mL avoided; £22,900 per case of PPH ≥ 1000 mL avoided; 
and £894,514 per major outcome averted.
Conclusion The results suggest carbetocin, oxytocin and ‘ergometrine plus oxytocin’ could all be favourable options for 
being the most cost-effective strategy for preventing PPH. Carbetocin could be the preferred choice, especially if the price 
of carbetocin decreased. Mixed findings mean a clear-cut conclusion cannot be made as to which uterotonic is the most cost 
effective. Future research should focus on collecting more robust evidence on the probability of having adverse events from 
the uterotonic drugs, and on adapting the model for low- and middle-income countries.
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Key Points for Decision Makers 
This cost-effectiveness analysis is the first analysis to 
analyse the relative cost effectiveness for the full range 
of uterotonic drugs available for preventing postpartum 
haemorrhage.
The results of this paper show carbetocin, oxytocin and 
‘ergometrine plus oxytocin’ to all be favourable options 
for the prevention of postpartum haemorrhage.
A small decrease in the price of carbetocin could make 
it the preferred uterotonic for preventing postpartum 
haemorrhage.
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1 Introduction
Postpartum haemorrhage (PPH) is a leading cause of 
maternal death worldwide [1]. PPH is defined as blood 
loss ≥ 500 mL from the genital tract within the first 24 h 
of birth [2], and maternal death is defined as the death of a 
woman while pregnant or within 42 days of termination of 
the pregnancy [3]. Uterotonic drugs administered at the birth 
of the baby are routinely recommended for the prevention 
of PPH for all women, but there is uncertainty over which 
uterotonic drug is best. Currently, in the UK [4] and glob-
ally [5], oxytocin is recommended for preventing PPH due 
to its relatively high effectiveness, relatively low incidence 
of adverse effects and low price.
A handful of other uterotonic drugs and combinations 
of uterotonic drugs are available, with properties lacking 
in oxytocin. For example, oxytocin requires refrigeration, 
which is not possible in some low- and middle-income coun-
try (LMIC) settings. Currently, misoprostol is recommended 
where oxytocin is unavailable [5], as misoprostol is heat 
stable and administration is easy, in the form of a tablet. 
Carbetocin is a synthetic, heat-stable version of oxytocin, 
with a similar side-effect profile [6, 7], which could make it 
a favourable alternative to oxytocin.
A few studies have compared the cost effectiveness of 
a single alternative uterotonic drug with standard care for 
the prevention of PPH [8–14]. A recent UK study found the 
uterotonic drug carbetocin to be cost saving compared with 
current practice oxytocin [15], but there are no published 
studies exploring more than two uterotonic drugs or any 
ranking of cost effectiveness for multiple uterotonic drugs.
In this paper, we report the results of a model-based eco-
nomic evaluation using effectiveness data from a network 
meta-analysis (NMA) [16]; alongside these, data on costs 
and resource use were collected prospectively. The objective 
of this economic evaluation was to compare the relative cost 
effectiveness of the full range of uterotonic drugs available 
for the prevention of PPH, for women delivering by vaginal 
delivery. The risk of a women having PPH differs depend-
ing on mode of delivery [17, 18]. Only women giving birth 
by vaginal delivery were included in this study. A separate 
analysis for caesarean section delivery is reported elsewhere 
[16].
2  Methods
A model was constructed to facilitate all the relevant com-
parisons in order to determine the most cost-effective 
uterotonic drug for the prevention of PPH. The analyses 
were carried out from the perspective of the UK National 
Health Service (NHS), as this was a UK-funded study. The 
primary outcome measure was cost per case of PPH avoided 
(≥ 500 mL blood loss). Secondary outcome measures of cost 
per case of severe PPH avoided (≥ 1000 mL) and cost per 
major outcome (surgery) averted were also analysed. The 
results are presented in terms of the incremental cost-effec-
tiveness ratio (ICER), namely the additional cost per case 
of PPH ≥ 500 mL avoided; additional cost per case of severe 
PPH ≥ 1000 mL avoided; and additional cost per major out-
come averted.
2.1  Model Structure
A decision tree model was developed to represent the alter-
native strategies. The pathways of the model follow national 
guidelines [4, 19] and were finalised using expert opinion 
from within the research study team. The pathways repre-
sent, as far as possible, the clinical steps carried out in a UK 
hospital in the event of PPH. The clinical pathways on which 
the decision tree is based are presented in Fig. 1. The full 
model structure is available in Appendix 1.
The model commences when women are approaching 
the third stage of labour, where the third stage of labour 
is defined as the period of time after the birth of the baby 
and before removal of the placenta and membranes [20]. 
At the prevention stage (Stage 0) of the model, women are 
given one of six active prevention strategies: carbetocin, 
ergometrine, ‘ergometrine plus oxytocin’, ‘misoprostol plus 
oxytocin’, misoprostol, and oxytocin.
It is assumed that after receiving a particular prevention 
strategy at stage 0, a woman will have a probability of either 
bleeding (PPH ≥ 500 mL) or experiencing no PPH. If a 
woman shows signs of continuing to bleed, she may require 
further treatment. Following WHO and UK guidelines [4, 
5, 19], it is possible that in some cases where a uterotonic 
drug has been given for prevention, it will be given again as 
treatment for PPH.
If, after the prevention stage, a woman continues to bleed, 
she will follow a consecutive series of four treatments. Each 
one is an attempt to stop the bleeding. The stages are as 
follows:
0. Prevention Stage.
1. Treatment Stage 1 If bleeding continues (≥ 1000 mL 
blood loss), the woman will be treated with a combina-
tion of two drugs: an oxytocin infusion and ‘ergometrine 
plus oxytocin’. (If this fails, she will enter treatment 
stage 2).
2. Treatment Stage 2 If bleeding continues, the woman will 
be treated with two alternative drugs: carboprost and 
misoprostol. (If this fails, she will enter treatment stage 
3).
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3. Treatment Stage 3 If bleeding continues, the woman will 
receive a minimally invasive balloon (balloon tampon-
ade). (If this fails, she will enter treatment stage 4).
4. Treatment Stage 4 If bleeding continues, a surgical pro-
cedure such as a hysterectomy will be carried out on the 
woman. The model allows death at this stage, but the 
probability of death is negligible.
2.2  Adverse Events
After receiving a drug for either prevention or treatment of 
PPH, a woman has a chance of having an adverse event. 
Adverse events considered possible in the model included 
nausea, vomiting, tachycardia, hypotension, hypertension, 
headache, fever, shivering, and abdominal pain. This is the 
complete list of adverse events found in the NMA.
The probability of a woman having adverse events and 
the associated costs were included in the models as weighted 
Fig. 1  Summarised version 
of the clinical pathways in the 
model
Woman at risk of PPH
after delivery
Uterotonic drug
Oxytocin Infusion and
Ergometrine plus Oxytocin
Carboprost and Misoprostol
Balloon Tamponade
Surgery
PPH
Bleeding Continues
Bleeding Continues
Bleeding Continues
Survive Die
No PPH
Bleeding Stops
Bleeding Stops
Bleeding Stops
Prevention
Treatment Stage 1
Treatment Stage 2
Treatment Stage 3
Treatment Stage 4
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averages. The costs are incurred after the woman has been 
given a uterotonic drug to prevent or treat PPH.
The third stage of labour can differ depending on mode 
of delivery. Given this, the current study was carried out for 
vaginal delivery only, which applies to the vast majority of 
births (75%) [21].
2.3  Effectiveness Data
The effectiveness data are presented in Table 1. The effec-
tiveness data required for the model were based on the 
results of the trials sourced from the NMA [16]. The NMA 
was comprised of 137 studies and 87,466 women. Where 
necessary, data were supplemented by other published lit-
erature. No data were available in the NMA for the effective-
ness of treatment stages 2, 3 and 4. These were sourced from 
the literature [22–25].
The NMA reported relative probabilities. For the health 
economic analysis, absolute probabilities were required. 
This required transforming the relative probabilities by using 
one main comparator. Oxytocin was deemed a suitable main 
comparator in the base case because it is currently recom-
mended for prevention of PPH in the UK [4], and because 
the NMA revealed a large number of studies comparing 
oxytocin with an alternative strategy, so data around the 
oxytocin strategy was considered to be the most robust.
The main clinical outcomes from the NMA were defined 
by blood loss ≥ 500 mL and ≥ 1000 mL. It was assumed that 
preventing PPH ≥ 500 mL meant non-progression beyond 
Stage 0 in the model, and correspondingly preventing 
PPH ≥ 1000 mL meant treatment at Stage 1 of the model, 
but no further treatment had been given.
Given all women in the model are exposed to prevention 
and treatment for PPH, the probability of death in the model 
is zero.
The probabilities of experiencing adverse events were 
sourced from the NMA [16]. Full details are presented in 
Appendix 2. The data for adverse events was not complete, 
and so assumptions were required to complete the dataset 
(see Sect. 2.5.2).
2.4  Resource Use and Costs
The study uses UK unit costs, as the current study is hosted 
and funded by UK research money. All costs sourced are 
reported in 2016 UK prices, having been appropriately 
inflated if necessary [26]. Key costs are presented in Table 2.
Delivery costs [27] were incurred at the start of the 
model. Standard practice dosage and routes of administration 
Table 1  Effectiveness data
a Probabilities of success are absolute probabilities converted from relative probabilities from the network meta-analysis (NMA), relative to the 
oxytocin arm. Oxytocin was deemed most suitable as the main comparator in the base case. The NMA revealed a large number of studies com-
paring oxytocin with an alternative strategy, so data around the oxytocin strategy was considered to be the most robust
b Standard errors shown are the standard errors for their respective relative probabilities. Where no standard errors for probabilities were provided 
in the literature estimates, they were calculated as a tenth of one minus its value [33]
c The effectiveness of treatment stage 4 (surgery) was based on a literature estimate for hysterectomy. Different surgical procedures can be carried 
out to treat postpartum haemorrhage (PPH) (laparotomy, B-Lynch suturing technique [brace suture]), but as a hysterectomy is the procedure usu-
ally used as a life-saving measure for PPH [23, 25], the source was considered appropriate
Item Description Probability of 
 successa
Standard  errorb Lower 95% 
CI (%)
Upper 95% 
CI (%)
Source
Prevention Oxytocin 0.908 0.009 0.891 0.925 Gallos et al. [16]
Prevention Carbetocin 0.944 0.288 0.883 0.974 Gallos et al. [16]
Prevention Ergometrine plus oxytocin 0.936 0.101 0.908 0.958 Gallos et al. [16]
Prevention Ergometrine 0.891 0.140 0.830 0.933 Gallos et al. [16]
Prevention Misoprostol plus oxytocin 0.931 0.144 0.892 0.958 Gallos et al. [16]
Prevention Misoprostol 0.899 0.078 0.861 0.929 Gallos et al. [16]
Treatment Stage 1 Oxytocin 0.977 0.003 0.971 0.997 Gallos et al. [16]
Treatment Stage 1 Carbetocin 0.988 0.756 0.932 0.244 Gallos et al. [16]
Treatment Stage 1 Ergometrine plus oxytocin 0.982 0.105 0.972 0.895 Gallos et al. [16]
Treatment Stage 1 Ergometrine 0.973 0.342 0.935 0.658 Gallos et al. [16]
Treatment Stage 1 Misoprostol plus oxytocin 0.981 0.176 0.966 0.824 Gallos et al. [16]
Treatment Stage 1 Misoprostol 0.970 0.060 0.958 0.940 Gallos et al. [16]
Treatment Stage 2 Carboprost 0.840 0.016 0.755 0.887 Butwick et al. [24]
Treatment Stage 3 Balloon tamponade 0.840 0.016 0.775 0.888 Doumouchtsis et al. [22]
Treatment Stage 4 Surgeryc 0.994 0.0006 0.85 1.00 Knight [23]
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were identified for each uterotonic drug (see Table 2), via 
the study team, and unit costs were taken from published 
sources [28, 29]. The total cost for the balloon tamponade 
procedure was £1280.42 (Table 2) [27]. A hysterectomy cost 
was £3780.40 (Table 2) [27]. It was assumed that a woman 
requiring treatment at Stage 4 (surgery, having already had 
a failed attempt at balloon tamponade) will remain in theatre 
throughout Stages 3 and 4. In order to avoid duplication of 
some costs by summing these procedures, women who ulti-
mately required the more serious intervention of hysterec-
tomy incurred only half of the cost for a balloon tamponade.
Table 2  Table of costs
CRP C-reactive protein, IM intramuscularly, IV intravenous, PPH postpartum haemorrhage
a During the probabilistic sensitivity analysis, a gamma distribution was fitted to model uncertainty. Because only a point estimate was available 
in the literature, the widest possible uncertainty was explored [33, 34]
Item Drug/treatment Unit cost (£) Other information Sources
Delivery costs Delivery costs associated 
with vaginal delivery
1826.04a per delivery. See Appendix 3 for 
breakdown of calculation
NHS reference costs [27]
Uterotonic drug Oxytocin 0.91 per 10 IU, intramuscularly British National Formulary [29]
Uterotonic drug Misoprostol 0.17 per 200 µg tablet National Electronic Drug Tariff [28]
Uterotonic drug Ergometrine 1.50 per 500 µg, intramuscularly British National Formulary [29]
Uterotonic drug Ergometrine + oxytocin 1.57 per 500 µg (ergometrine) + 5 IU, 
intramuscularly (oxytocin)
British National Formulary [29]
Uterotonic drug Misoprostol plus oxytocin 1.08 per person (cost of misoprostol + cost 
of oxytocin)
British National Formulary [29], 
National Electronic Drug Tariff [28]
Uterotonic drug Carbetocin 17.64 per 100 µg, intramuscular British National Formulary [29]
Treatment for PPH Oxytocin infusion 0.91 per 10 IU, infusion British National Formulary [29]
Treatment for PPH Carboprost 18.2 per 250 µg, intramuscular British National Formulary [29]
Treatment for PPH Balloon tamponade 1280.42a Per procedure NHS reference costs [27]
Treatment for PPH Postpartum surgery 3780.40a Per procedure NHS reference costs [27]
Treatment for PPH Blood transfusion 171.84–163.63a Per unit £171.84 (1st unit), £163.63 
(subsequent units)
National Institute for Health and Care 
Research [31]
Hospital stay Excess bed days 440.49a Per excess day in hospital. The figure 
is a weighted average of all excess 
bed-day costs for a vaginal delivery 
(normal or assisted) within an inpa-
tient setting (see Appendix 5)
NHS reference costs [27]
Adverse event Nausea 28.50a Per event. Cyclizine (50 mg, twice, 
IV injection) and ondansetron 
(4 mg twice, IM)
British National Formulary [29]
Adverse event Vomiting 442.05a Per event. Prochlorperazine (12.5 mg 
3 times daily, IM) with IV fluids 
– 24 h
NHS reference costs [27], British 
National Formulary [29]
Adverse event Hypertension 630.55a Per event. Labetalol (200 mg over 
24 h) and nifedipine (20 mg over 
24 h, orally)
NHS reference costs [27], British 
National Formulary [29]
Adverse event Headache 0.66a Per event. Paracetamol and codeine 
for 24 h
British National Formulary [29]
Adverse event Tachycardia 440.49a Per event. Observation over 24 h NHS reference costs [27]
Adverse event Hypotension 440.49a Per event. IV fluids and observation 
over 24 h
NHS reference costs [27]
Adverse event Fever 443.04a Per event. Paracetamol and IV antibi-
otics with fluids. Observation over 
24 h, including a blood culture, 
high vaginal swab, full blood count 
and CRP test
NHS reference costs [27], British 
National Formulary [29]
Adverse event Shivering 440.49a Per event. Observation over 24 h NHS reference costs [27]
Adverse event Abdominal pain 0.25a Per event. Paracetamol and oral 
morphine for 24 h
British National Formulary [29]
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The assumed lengths of hospital stay were based on blood 
loss and are based on real data from Birmingham Women’s 
Hospital, UK, and supplemented by published literature [30] 
(Appendix 4). The associated cost attached to an extra day 
in hospital was £440.49 (Table 2).
Treatments for adverse events in their worst case were 
sought via expert opinion, which consisted of a team of five 
obstetricians. The experts’ opinions were put forward and 
debated and discussed until consensus was reached to which 
they could all comply. The obstetricians were part of the 
research team.
Other resource implications and costs would be associ-
ated with blood transfusion [31]. Based on expert opinion, 
two units of blood were assumed to be given to women 
reaching treatment Stage 3 and an additional two units of 
blood were assumed to be given to women reaching treat-
ment Stage 4 of the models.
A full breakdown of how unit costs were calculated is 
provided in the Appendices (Appendix 3 and Appendix 5).
2.5  Assumptions
In addition to those already described, several assumptions 
were required in order to develop a workable model. These 
are described below. All assumptions were agreed and final-
ised within the clinical research team prior to the analysis.
2.5.1  Model Structure
1. No routine uterotonic drug for PPH has been adminis-
tered to women prior to them entering the model.
2. All prevention strategies (Stage 0) are followed by the 
same stages of treatment (Stages 1–4), except for where 
misoprostol is given for prevention, either alone or as 
part of a combination drug. Following expert opinion, 
misoprostol may not be given for treatment if it has 
already been given for prevention of PPH. In the case 
where misoprostol has been given for prevention, and 
the patient requires Stage 2 treatment (carboprost and 
misoprostol), the patient will forgo the misoprostol and 
only receive carboprost. Misoprostol is not replaced by 
another drug or form of treatment.
3. After ‘no PPH’, ‘bleeding stops’ and ‘survive’ pathways, 
women will return to full health.
4. A chance of death can only occur after treatment Stage 
4.
5. All births are assumed to take place in an obstetric unit, 
where appropriate treatment for PPH is readily avail-
able should the women require it. This is true of 87% of 
births in the UK [21].
6. The model runs for the immediate postpartum period 
only.
2.5.2  Adverse Events
1. Based on the evidence from the NMA and pharmaco-
logical knowledge, it was assumed that the adverse event 
profile of carbetocin and oxytocin is similar. Similarly, 
the adverse event profile of ‘ergometrine plus oxytocin’ 
was assumed to be similar to ergometrine, and the 
adverse event profile of ‘misoprostol plus oxytocin’ to 
be similar to misoprostol alone.
2. If data were missing for carbetocin, but available for 
oxytocin, then the probability for the adverse event was 
based on oxytocin. This reasoning was applied to other 
similar uterotonic agents.
3. If data were missing for both uterotonic agents with 
the same adverse events profile (e.g. data were missing 
for both carbetocin and oxytocin), then an average of 
the probabilities available for that side effect was used. 
Ergometrine is commonly known to be associated with 
a high level of all side effects, with the exceptions of 
fever and shivering. So uterotonic drugs containing 
ergometrine were removed from the averaging process, 
apart from when considering fever and shivering. Mis-
oprostol is commonly known to be associated with fever 
and shivering [32], so uterotonic drugs containing mis-
oprostol were removed from the averaging process for 
these adverse events.
2.5.3  Cost and Resource Use
1. Costs for uterotonic drugs were assumed to be standard 
across the model. That is, they are assumed to carry 
the same cost, regardless of whether they are given for 
prevention or treatment.
2. Costs for administration of treatment (i.e. staff time) 
were assumed to be included in delivery costs and excess 
bed-day costs. Administration costs were assumed to be 
broadly captured by the cost of delivery (Appendix 3). 
No extra staff costs were therefore attached to treatment 
costs of PPH.
3. An outcome of death assumed no excess bed-day costs.
4. The effectiveness of treatments used for adverse events 
were assumed to be 100% successful.
5. The cost of treatment for adverse events, as a weighted 
average, was attached to every outcome of the model, 
except death. That is, unless a woman died, she would 
incur costs for treatment for adverse events, based on the 
probability that an adverse event occurs.
2.6  Analysis
Two alternative analyses were carried out. Because of the 
multiple missing data for adverse events, analysis was 
carried out including and excluding adverse events. Each 
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analysis was carried out for the following three outcome 
measures:
(a) Cost per case of PPH ≥ 500 mL avoided.
(b) Cost per case of PPH ≥ 1000 mL avoided.
(c) Cost per major outcome averted, where a major out-
come refers to treatment stage 4 of the model (surgery).
2.6.1  Analysis 1
Analysis 1 was a deterministic analysis of the relative cost 
effectiveness for a range of uterotonic drugs for the preven-
tion of PPH for vaginal delivery. This analysis excludes any 
information on adverse events. The results are presented as 
ICERs.
2.6.2  Analysis 2
Analysis 2 was a deterministic analysis similar to Analysis 
1, but adverse events were included in this analysis.
2.6.3  Sensitivity Analyses
A probabilistic sensitivity analysis (PSA) was carried out 
to explore the uncertainty of the model input data. In PSA, 
distributions are assigned to all uncertain model parameters, 
and by drawing randomly from these distributions, a large 
number (10,000) of mean cost and effectiveness estimates 
are generated. These estimates are used jointly to form an 
empirical distribution of the differences in cost and effec-
tiveness of interventions. A normal distribution was fitted 
to absolute probabilities, and a beta distribution was fitted 
to model uncertainty in relative probabilities used in the 
model [33]. There is no uncertainty around unit costs so 
no distribution was fitted. Resource use is uncertain and so 
costs including resource use have a confidence interval. Only 
point estimates for uncertain costs were available in the lit-
erature, and in these cases a gamma distribution was fitted, 
and the widest possible uncertainty applied [33, 34]. The 
PSA was carried out for Analysis 2, based on the outcome 
measure of ‘cost per case of PPH ≥ 500 mL avoided’ only.
The majority of the carbetocin trials included in the NMA 
consist of a small sample population [16]. Carbetocin is the 
most effective strategy, and is known to have a favourable 
adverse event profile, similar to oxytocin [6, 7]. However, 
carbetocin has a much higher unit cost than the other utero-
tonic drugs. A threshold analysis was therefore carried out 
to see the effect on the results if the price of carbetocin was 
lowered.
3  Results
We report the results for the separate analyses according to 
the outcome upon which the analysis was based (outcome 
measures a, b, c). The results of the analyses are summarised 
in Table 3.
3.1  Analysis 1
Deterministic analysis exploring the relative cost effective-
ness for a range of uterotonic drugs for the prevention of 
PPH for vaginal delivery. Adverse events are excluded from 
this analysis.
(a) ‘Ergometrine plus oxytocin’ is the least costly preven-
tion strategy with an average cost of £2538 per woman 
(Table 3). The strategy in which carbetocin is given as 
the uterotonic drug for prevention is the most effec-
tive, and ‘ergometrine plus oxytocin’ is the second most 
effective strategy. All other prevention strategies are 
dominated by ‘ergometrine plus oxytocin’, as they are 
both more costly and less effective than ‘ergometrine 
plus oxytocin’. The estimated ICER for prevention with 
carbetocin compared with prevention with ‘ergometrine 
plus oxytocin’ was £1889 per case of PPH ≥ 500 mL 
avoided. This means that every additional case of 
PPH ≥ 500 mL avoided by using carbetocin over ‘ergo-
metrine plus oxytocin’, costs an extra £1889 (Table 3).
(b) For the outcome in terms of PPH ≥ 1000 mL avoided, 
the results in an ICER for prevention with carbetocin 
compared with prevention with ‘ergometrine plus oxy-
tocin’ was £30,013 per case of PPH ≥ 1000 mL avoided 
(Table 3).
(c) For the outcome measure of major outcome averted, 
the ICER for prevention with carbetocin compared 
with prevention with ‘ergometrine plus oxytocin’ was 
£1,172,378 per major outcome averted (Table 3).
3.2  Analysis 2
Adverse events are included in this analysis.
(a) Oxytocin is the least costly prevention strategy with an 
average cost of £2618 per woman (Table 3). Carbetocin 
is the most effective strategy, and oxytocin is the fourth 
most effective strategy. All other prevention strategies 
are dominated by carbetocin as the strategy of carbe-
tocin is relatively more effective and less costly. The 
ICER for prevention with carbetocin compared with 
prevention with oxytocin was estimated to be £928 per 
case of PPH ≥ 500 mL avoided.
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(b) For the outcome in terms of PPH ≥ 1000 mL avoided, 
the ICER for prevention with carbetocin compared 
with prevention with oxytocin was £22,900 per case of 
PPH ≥ 1000 mL avoided.
(c) For the outcome measure of major outcome averted, 
the ICER for prevention with carbetocin compared with 
prevention with oxytocin was £894,514 per major out-
come averted.
3.3  Sensitivity Analysis
3.3.1  Probabilistic Sensitivity Analysis (PSA) of Analysis 2
The cost-effectiveness acceptability curve (CEAC) shows the 
probability that each intervention is cost effective, compared 
with the alternative, for a range of values of the maximum 
acceptable ceiling ratio [35]. As the willingness-to-pay (WTP) 
per PPH ≥ 500 mL avoided tends to infinity, the probability 
that carbetocin is cost effective compared with oxytocin tends 
to 95%. The difference in probabilities over the WTP reflects 
some uncertainty in the model. The CEAC for leading strate-
gies carbetocin and oxytocin is presented in Fig. 2.
3.3.2  Threshold Analysis (Lowering the Price of Carbetocin)
The results of the threshold analysis are presented in Table 4.
In Analysis 1, the leading strategies are carbetocin and 
‘ergometrine plus oxytocin’. When the price of carbetocin 
is lowered from £17.64 to £3.88, carbetocin becomes the 
dominant strategy (least costly and most effective).
In Analysis 2, the leading strategies are carbetocin and oxy-
tocin. Lowering the price of carbetocin made no difference 
to the results in this analysis, because the results were most 
sensitive to adverse events. The low costs attached to adverse 
events for oxytocin, compared with the adverse events of car-
betocin, resulted in oxytocin always being a leading strategy.
3.3.3  Additional One‑Way Sensitivity Analyses
Additional one-way sensitivity analyses were conducted 
that changed the cost of treatment stage 4 (surgery) and the 
effectiveness of treatment stage 2 (carboprost). These are not 
reported as they showed no difference to the results.
4  Discussion
This study explores the relative cost effectiveness for the full 
range of uterotonic drugs at preventing PPH in all women 
having a vaginal delivery. In this study, limited data around 
adverse events meant that two analyses were required: one 
analysis excluding adverse events (Analysis 1), and a second 
analysis including adverse events, using best available data 
supplemented by assumptions (Analysis 2).
Both analyses show that carbetocin is the most effective 
prevention strategy.
Table 3  Summary of results
In general, results are given to 3 decimal places. Where rounding resulted in identical effectiveness ratios, effectiveness ratios are given to 6 
decimal places
All costs are rounded to nearest £
PPH postpartum haemorrhage
a ICER: incremental cost-effectiveness ratio expressed as the additional cost per additional case of PPH (≥ 500 mL) avoided
Cost per average 
woman (£)
PPH (≥ 500 mL) avoided PPH (≥ 1000 mL) avoided Major outcome averted
Effectiveness ICERa (£) Effectiveness ICERa (£) Effectiveness ICERa (£)
Analysis 1 (excluding adverse events)
 Ergometrine + oxytocin 2538 0.936 0.998843 0.999970
 Carbetocin 2551 0.944 1889 0.999301 30,013 0.999982 1172,378
 Misoprostol + oxytocin 2539 0.931 Dominated 0.998843 Dominated 0.999966 Dominated
 Oxytocin 2545 0.908 Dominated 0.998668 Dominated 0.999946 Dominated
 Misoprostol 2548 0.899 Dominated 0.997859 Dominated 0.999924 Dominated
 Ergometrine 2551 0.891 Dominated 0.996982 Dominated 0.999926 Dominated
Analysis 2 (including adverse events)
 Oxytocin 2618 0.908 0.997859 0.999945
 Carbetocin 2650 0.944 928 0.999301 22,900 0.999982 894,514
 Ergometrine + oxytocin 2662 0.936 Dominated 0.998843 Dominated 0.999970 Dominated
 Ergometrine 2752 0.891 Dominated 0.997082 Dominated 0.999925 Dominated
 Misoprostol + oxytocin 2762 0.931 Dominated 0.998668 Dominated 0.999966 Dominated
 Misoprostol 2772 0.899 Dominated 0.996982 Dominated 0.999923 Dominated
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In Analysis 1, ‘ergometrine plus oxytocin’ is the least 
costly prevention strategy, and the ICER for prevention 
with carbetocin compared with prevention with ‘ergo-
metrine plus oxytocin’ was estimated to be £1889 per case of 
PPH ≥ 500 mL avoided; £30,013 per case of PPH ≥ 1000 mL 
avoided; and £1,172,378 per major outcome averted.
In Analysis 2, oxytocin is the least costly prevention strat-
egy. The respective ICERs for prevention with carbetocin 
compared with prevention with oxytocin was estimated to be 
£928 per case of PPH ≥ 500 mL avoided; £22,899.57 per case 
of PPH ≥ 1000 mL avoided; and £894,514 per major outcome 
averted.
The leading strategies across both analyses were carbe-
tocin, oxytocin and ‘ergometrine plus oxytocin’.
‘Ergometrine plus oxytocin’ and carbetocin were the lead-
ing strategies in Analysis 1, where no adverse events were 
included. However, there are reservations around the use of 
ergometrine for the prevention of PPH because of its relatively 
higher prevalence of adverse events and its known correla-
tion with an increased risk of stroke [36], which is strongly 
associated with hypertension. The threshold analysis showed 
lowering the cost of carbetocin to £3.88 per dose would make 
carbetocin the dominant strategy. But, as a result of the rela-
tively high prevalence of adverse events for ergometrine, in 
reality carbetocin is likely to perform relatively better than 
suggested in Analysis 1 and in the threshold analysis.
In Analysis 2 (adverse events included), oxytocin and car-
betocin were the leading strategies. The threshold analysis 
(lowering the cost of carbetocin) showed no effect here, dis-
playing that oxytocin was a leading strategy in this analysis 
because of its favourable adverse events profile, relative to 
the other uterotonic drugs. Overall, in Analysis 2, the costs 
associated with adverse events from oxytocin were lower 
than the costs associated with adverse events from carbetocin. 
The adverse events data for carbetocin were incomplete. It is 
unclear how robust these limited data are on adverse events 
associated with carbetocin. In this study, the adverse events 
attached to carbetocin are shown to be worse than adverse 
events attached to oxytocin. However, in the published lit-
erature, carbetocin is found to have a similar adverse events 
profile to oxytocin [6, 7], and so in reality, carbetocin is likely 
to perform slightly better than suggested in Analysis 2.
PPH is a leading cause of maternal death worldwide [1]; 
however, in the model no one died, because women were 
assumed to follow a series of treatments in an attempt to stop 
bleeding. There is a small risk of death if the woman reaches 
treatment stage 4 (surgery), but the surgical procedure would 
Fig. 2  Cost-effectiveness 
acceptability curve between pre-
vention strategies oxytocin and 
carbetocin, using distributions 
around the accuracy data
Table 4  Threshold analysis: 
altering the price of carbetocin Other prevention strategies not dominated
Price at which carbetocin becomes dominant 
strategy (least costly and most effective) (£)
Analysis 1 Ergometrine plus oxytocin 3.88
Analysis 2 Oxytocin Carbetocin never dominates oxytocin
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stop the bleeding, so any risk of death is associated with 
complications arising from surgery.
A strength of this analysis is that it is the first model-
based economic evaluation to compare the cost effective-
ness of six different active strategies for preventing PPH. By 
using effectiveness data from an NMA, it is ensured that the 
pooled effectiveness data is a good reflection of the effec-
tiveness of the prevention strategies, as opposed to a ran-
domised control trial that may have several biases attached.
A limitation is that data were missing from the NMA. 
Attempts were made to make missing probabilities as accurate 
as possible, and the impact of adverse events was explored in 
the PSA. There is some uncertainty around the accuracy of the 
length of hospital stay data, as this was collected from only one 
hospital, because it was not available from the NMA. It was 
beyond the scope of the paper to analyse comparisons for dif-
ferent dosages of uterotonic drugs or different routes of admin-
istration. A further limitation is that the outcomes of the study 
are in natural units as quality-of-life information was not avail-
able in this analysis. This makes the results difficult to interpret 
as there is no explicit acceptable cost-effectiveness threshold.
This study takes the perspective of the UK NHS and, 
based on secondary data, it is not possible to present a wider 
perspective. The study may be generalizable to other high-
income country settings where available resources and rela-
tive costs are similar to the UK. The results of this study may 
not be generalizable to some LMIC settings where resources 
are limited. However, rates of morbidity and mortality from 
PPH are much higher in LMICs [37], and this information 
is highly relevant for LMIC settings. Future research could 
adapt this model and its use of the effectiveness data, which 
relates to globally synthesised data, in the meta-analysis to 
carry out a cost-effectiveness analysis from an LMIC per-
spective. The choice of uterotonic drugs used in such an 
analysis should be considered as well as the availability of 
resources. For example, oxytocin requires cold chain stor-
age, which may not be feasible in some LMIC settings.
Van der Nelson et al. [15] recently published a study explor-
ing the cost effectiveness of carbetocin versus oxytocin for the 
prevention of PPH, but for caesarean section only, and pre-
sented a lower mean cost per woman compared with the current 
analysis. We cannot directly compare the results of this study 
and the results of the study by van der Nelson et al. because 
this study is for vaginal delivery only and van der Nelson et al. 
considers caesarean section only. Delivery costs are included in 
this study but not included in van der Nelson et al., which may 
be a contributing factor in the relatively lower mean cost per 
woman found in van der Nelson et al. Adverse events are also 
not included in van der Nelson’s model, which may be an addi-
tional contributing factor to the lower mean cost per woman.
Since the network meta-analysis was carried out, evi-
dence was published showing that tranexamic acid is an 
effective treatment for PPH [38]. This study is concerned 
with the prevention of PPH and thus including tranexamic 
acid as a treatment in each prevention strategy of the model 
is unlikely to impact on the relative cost effectiveness of the 
prevention strategies.
5  Conclusion
Given WHO and UK guidelines recommend uterotonic drugs 
for the prevention of PPH, the results of this study suggest 
that UK current practice (oxytocin), carbetocin and ‘ergo-
metrine plus oxytocin’ are the preferred strategies based on 
their relative cost effectiveness. Because of its high effective-
ness and low incidence of adverse events, carbetocin could 
be the favoured uterotonic, especially if the price of carbe-
tocin was reduced. Mixed findings across the analyses means 
that the findings of this study are insufficient on their own 
to dictate changes in practice. Future research should focus 
on gaining more concrete evidence on the adverse events 
attached to uterotonic drugs, as the model was sensitive to 
the costs applied to adverse events. Future research should 
also focus on adapting this model structure for LMICs, where 
rates of mortality and morbidity from PPH are much higher.
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Appendix 1
Appendix 2: Probability of adverse events for each prevention strategy
Prevention 
strategy
Probability of adverse event (standard errors in parenthesis)
Nausea Vomiting Hyperten-
sion
Headache Tachycardia Hypoten-
sion
Fever Shivering Abdominal 
Pain
Oxytocin 0.039 0.010 0.021 0.044 0.025 0.005 0.020 0.071 0.134
(0.005) (0.002) (0.005) (0.009) (0.014) (0.005) (0.003) (0.007) (0.043)
Misoprostol 
plus oxytocin
0.270 0.039 * * * * 0.090 0.261 *
(0.891) (0.255) (0.229) (0.246)
Misoprostol 0.058 0.029 0.033 0.068 * 0.002 0.105 0.271 0.127
(0.161) (0.097) (0.655) (0.323) (1.630) (0.162) (0.140) (0.158)
Ergometrine 
plus oxytocin
0.081 0.043 0.059 0.072 0.040 * 0.020 0.087 0.149
(0.202) (0.099) (0.633) (0.294) (0.551) (0.336) (0.282) (0.245)
Ergometrine 0.106 0.042 0.172 0.129 * * 0.020 0.097 0.172
(0.226) (0.148) (0.814) (0.412) (0.303) (0.265) (0.464)
Carbetocin 0.028 0.010 0.030 0.054 0.074 * * * 0.099
(0.341) (0.305) (0.808) (0.382) (0.498) (0.307)
Source: Gallos et al. [16]
*Means data is missing
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Appendix 3: Breakdown of delivery costs
Setting Activity National average  
unit cost (£)
Sources
Vaginal delivery (normal and assisted)
Elective inpatient 1362 2038.40 NHS Reference Costs [27]a
Non-elective long stay 139,514 2634.20 NHS Reference Costs [27]a
Non-elective short stay 223,663 1322.60 NHS Reference Costs [27]a
Day case 77 418.51 NHS Reference Costs [27]a
Total 364,616 1826.95
Minus average UK standard practice for preventing and treating postpar-
tum haemorrhage (PPH) (oxytocin 10 IU, intramuscular injection)
0.91 British National Formulary [29]
Total cost of delivery 1826.04
NB Delivery costs are calculated for all levels of co-morbidities and complications. It is assumed therefore, that the costs for any other complica-
tions other than PPH are included in the delivery costs
The values in bold are the costs used in the economic analysis
a National average unit costs are weighted averages of the NHS reference costs for vaginal delivery (normal and assisted) without a postpartum 
surgical intervention in all inpatient settings. The types of delivery include: Normal Delivery with CC Score 0–2 + , Normal Delivery, with Epi-
dural or Induction, with CC Score 0–2 + , Assisted Delivery with CC Score 0–2 + , Assisted Delivery, with Epidural or Induction, with CC Score 
0–2 + (where CC stands for complications and comorbidities)
Appendix 4: Mean length of hospital stay
Blood loss (mL) Stage of model Mean length of hospital stay (days) Sources
<500 No PPH after prevention stage 1.57 BWHa
≥ 500 Bleeding stops after treatment stage 1 2.2 BWHa
≥ 1000 Bleeding stops after treatment stage 2 2.6 BWHa
≥ 1500 Bleeding stops after treatment stage 3 3 BWHa
Bleeding stops after treatment stage 4 6 Glaze et al. [30]
Table shows mean length of hospital stay for each stage of the decision tree model
Data was real data obtained from Birmingham Women’s Hospital (BWH). The data were collected from BWH for 2000 patients over a 3 month 
period (March–May 2016). The data were retrieved through K2 Medical Systems™: Athena™ Maternity Information System
Appendix 5: Breakdown of excess bed day costs
Setting Activity National average unit cost (£) Sources
Vaginal delivery (normal and assisted)
Elective inpatient excess bed days 173 432.56 1
Non-elective excess bed days 58,278 440.51 1
Total 58,451 440.49
Sourced from NHS Reference Costs (2014–2015) [27]. National average unit costs are weighted averages of the NHS reference costs for excess bed 
days associated with vaginal delivery (normal and assisted). The types of delivery include: Normal Delivery with CC Score 0–2 + , Normal Delivery, 
with Epidural or Induction, with CC Score 0–2 + , Normal Delivery, with Epidural and Induction, or with Post-Partum Surgical Intervention, with 
CC Score 0–2 + , Normal Delivery, with Epidural or Induction, and with Post-Partum Surgical Intervention, with CC Score 0–2 + , Normal Delivery, 
with Epidural, Induction and Post-Partum Surgical Intervention, with CC Score 0–2 + , Assisted Delivery with CC Score 0–2 + , Assisted Delivery, 
with Epidural or Induction, with CC Score 0–2 + , Assisted Delivery, with Epidural and Induction, or with Post-Partum Surgical Intervention, with 
CC Score 0–2 + , Assisted Delivery, with Epidural or Induction, and with Post-Partum Surgical Intervention, with CC Score 0–2 + , Assisted Delivery, 
with Epidural, Induction and Post-Partum Surgical Intervention, with CC Score 0–2 + (where CC stands for complications and comorbidities)
The value in bold is the cost used in the economic analysis
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